Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway

Table 2 OAT patients’ HRQoL and self-perceived health at baseline and follow up as measured by the EQ-5D-5L

	EQ-5D-5L VAS, baseline		EQ-5D-5L VAS, baseline^a		EQ-5D-5L VAS, follow-up		EQ-5D-5L Index		EQ-5D-5L Index		EQ-5D-5L Index
	n 609		n 245		n 245		n 609, baseline		n 245, baseline^a		n 245, follow-up
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Overall	57	22	57	22	59	22	0.699	0.250	0.691	0.237	0.729	0.237
Gender
Female	56	23	57	25	57	23	0.653	0.260	0.613	0.273	0.669	0.261
Male	57	22	57	21	60	22	0.718	0.243	0.716	0.220	0.748	0.226
Age group
< 25	58	18	55	19	61	25	0.787	0.164	0.766	0.211	0.678	0.390
26–40	61	22	59	22	60	22	0.724	0.242	0.689	0.234	0.745	0.205
41–60	54	22	55	22	58	22	0.684	0.253	0.686	0.238	0.716	0.253
≥61	51	23	56	16	58	16	0.613	0.292	0.714	0.257	0.754	0.210
OAT medication
Methadone	53	22	54	21	58	23	0.636	0.260	0.657	0.228	0.686	0.236
Buprenorphine	58	22	58	22	60	22	0.726	0.235	0.716	0.238	0.758	0.232
Buprenorphine/ naloxone	65	21	59	30	54	26	0.775	0.242	0.558	0.352	0.737	0.335

OAT Opioid agonist therapy, SD Standard deviation
Index obtained from Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2018. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England. Health Economics
^aBaseline values for the 245 patients who were eligible for follow-up analysis
The possible range of scores for EQ-5D-5L (0–1, 0 = dead (scores < 0 is possible), 1 = full health) and EQ-VAS (0–100, 0 = worst health imaginable, 100 = best health imaginable
Statistically significant changes are marked in bold (p < 0.05)

ISSN: 1747-597X